Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis

Background: Immunotherapeutic approaches, including immune checkpoint inhibitor (ICI) therapy, are increasingly recognized for their potential. Despite notable successes, patient responses to these treatments vary significantly. The absence of reliable predictive and prognostic biomarkers hampers th...

Full description

Saved in:
Bibliographic Details
Main Authors: Möller, Maximilian (Author) , Orth, Vanessa (Author) , Umansky, Viktor (Author) , Hetjens, Svetlana (Author) , Braun, Volker (Author) , Reißfelder, Christoph (Author) , Hardt, Julia (Author) , Seyfried, Steffen (Author)
Format: Article (Journal)
Language:English
Published: 24 May 2024
In: Frontiers in immunology
Year: 2024, Volume: 15, Pages: 1-14
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1403771
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2024.1403771
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1403771/full
Get full text
Author Notes:Maximilian Möller, Vanessa Orth, Viktor Umansky, Svetlana Hetjens, Volker Braun, Christoph Reißfelder, Julia Hardt and Steffen Seyfried

MARC

LEADER 00000caa a2200000 c 4500
001 1906964521
003 DE-627
005 20241205183057.0
007 cr uuu---uuuuu
008 241028s2024 xx |||||o 00| ||eng c
024 7 |a 10.3389/fimmu.2024.1403771  |2 doi 
035 |a (DE-627)1906964521 
035 |a (DE-599)KXP1906964521 
035 |a (OCoLC)1475317131 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Möller, Maximilian  |e VerfasserIn  |0 (DE-588)1346320489  |0 (DE-627)1906965412  |4 aut 
245 1 0 |a Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy  |b systematic review and meta-analysis  |c Maximilian Möller, Vanessa Orth, Viktor Umansky, Svetlana Hetjens, Volker Braun, Christoph Reißfelder, Julia Hardt and Steffen Seyfried 
264 1 |c 24 May 2024 
300 |b Illustrationen 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.10.2024 
520 |a Background: Immunotherapeutic approaches, including immune checkpoint inhibitor (ICI) therapy, are increasingly recognized for their potential. Despite notable successes, patient responses to these treatments vary significantly. The absence of reliable predictive and prognostic biomarkers hampers the ability to foresee outcomes. This meta-analysis aims to evaluate the predictive significance of circulating myeloid-derived suppressor cells (MDSC) in patients with solid tumors undergoing ICI therapy, focusing on progression-free survival (PFS) and overall survival (OS). Methods: A comprehensive literature search was performed across PubMed and EMBASE from January 2007 to November 2023, utilizing keywords related to MDSC and ICI. We extracted hazard ratios (HRs) and 95% confidence intervals (CIs) directly from the publications or calculated them based on the reported data. A hazard ratio greater than 1 indicated a beneficial effect of low MDSC levels. We assessed heterogeneity and effect size through subgroup analyses. Results: Our search yielded 4,023 articles, of which 17 studies involving 1,035 patients were included. The analysis revealed that patients with lower levels of circulating MDSC experienced significantly improved OS (HR=2.13 [95% CI 1.51–2.99]) and PFS (HR=1.87 [95% CI 1.29–2.72]) in response to ICI therapy. Notably, heterogeneity across these outcomes was primarily attributed to differences in polymorphonuclear MDSC (PMN-MDSC) subpopulations and varying cutoff methodologies used in the studies. The monocytic MDSC (M-MDSC) subpopulation emerged as a consistent and significant prognostic marker across various subgroup analyses, including ethnicity, tumor type, ICI target, sample size, and cutoff methodology. Conclusions: Our findings suggest that standardized assessment of MDSC, particularly M-MDSC, should be integral to ICI therapy strategies. These cells hold the promise of identifying patients at risk of poor response to ICI therapy, enabling tailored treatment approaches. Further research focusing on the standardization of markers and validation of cutoff methods is crucial for integrating MDSC into clinical practice. 
650 4 |a biomarkers 
650 4 |a immune checkpoint inhibitors 
650 4 |a Immunotherapy 
650 4 |a MDSC 
650 4 |a myeloid-derived suppressor cells 
650 4 |a Neoplasms 
650 4 |a prognosis 
650 4 |a Solid malignancies 
700 1 |a Orth, Vanessa  |e VerfasserIn  |0 (DE-588)1319592430  |0 (DE-627)1881031195  |4 aut 
700 1 |a Umansky, Viktor  |d 1955-  |e VerfasserIn  |0 (DE-588)102885756X  |0 (DE-627)731733207  |0 (DE-576)376300078  |4 aut 
700 1 |a Hetjens, Svetlana  |d 1983-  |e VerfasserIn  |0 (DE-588)1031801979  |0 (DE-627)737600284  |0 (DE-576)379534223  |4 aut 
700 1 |a Braun, Volker  |d 1972-  |e VerfasserIn  |0 (DE-588)1043808930  |0 (DE-627)770950825  |0 (DE-576)395926858  |4 aut 
700 1 |a Reißfelder, Christoph  |d 1975-  |e VerfasserIn  |0 (DE-588)1025566211  |0 (DE-627)722940297  |0 (DE-576)370516044  |4 aut 
700 1 |a Hardt, Julia  |d 1983-  |e VerfasserIn  |0 (DE-588)141404299  |0 (DE-627)62729796X  |0 (DE-576)183827643  |4 aut 
700 1 |a Seyfried, Steffen  |d 1988-  |e VerfasserIn  |0 (DE-588)1164103199  |0 (DE-627)102848996X  |0 (DE-576)508380391  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in immunology  |d Lausanne : Frontiers Media, 2010  |g 15(2024), Artikel-ID 1403771, Seite 1-14  |h Online-Ressource  |w (DE-627)657998354  |w (DE-600)2606827-8  |w (DE-576)343624834  |x 1664-3224  |7 nnas  |a Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy systematic review and meta-analysis 
773 1 8 |g volume:15  |g year:2024  |g elocationid:1403771  |g pages:1-14  |g extent:14  |a Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy systematic review and meta-analysis 
856 4 0 |u https://doi.org/10.3389/fimmu.2024.1403771  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1403771/full  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20241028 
993 |a Article 
994 |a 2024 
998 |g 1164103199  |a Seyfried, Steffen  |m 1164103199:Seyfried, Steffen  |d 60000  |d 61800  |d 60000  |e 60000PS1164103199  |e 61800PS1164103199  |e 60000PS1164103199  |k 0/60000/  |k 1/60000/61800/  |k 0/60000/  |p 8  |y j 
998 |g 141404299  |a Hardt, Julia  |m 141404299:Hardt, Julia  |d 60000  |d 61800  |d 60000  |e 60000PH141404299  |e 61800PH141404299  |e 60000PH141404299  |k 0/60000/  |k 1/60000/61800/  |k 0/60000/  |p 7 
998 |g 1025566211  |a Reißfelder, Christoph  |m 1025566211:Reißfelder, Christoph  |d 50000  |d 60000  |d 61800  |e 50000PR1025566211  |e 60000PR1025566211  |e 61800PR1025566211  |k 0/50000/  |k 0/60000/  |k 1/60000/61800/  |p 6 
998 |g 1043808930  |a Braun, Volker  |m 1043808930:Braun, Volker  |d 60000  |e 60000PB1043808930  |k 0/60000/  |p 5 
998 |g 1031801979  |a Hetjens, Svetlana  |m 1031801979:Hetjens, Svetlana  |d 60000  |d 60200  |d 60250  |e 60000PH1031801979  |e 60200PH1031801979  |e 60250PH1031801979  |k 0/60000/  |k 1/60000/60200/  |k 2/60000/60200/60250/  |p 4 
998 |g 102885756X  |a Umansky, Viktor  |m 102885756X:Umansky, Viktor  |d 140000  |d 910000  |d 911300  |e 140000PU102885756X  |e 910000PU102885756X  |e 911300PU102885756X  |k 0/140000/  |k 0/910000/  |k 1/910000/911300/  |p 3 
998 |g 1319592430  |a Orth, Vanessa  |m 1319592430:Orth, Vanessa  |d 60000  |d 61800  |e 60000PO1319592430  |e 61800PO1319592430  |k 0/60000/  |k 1/60000/61800/  |p 2 
998 |g 1346320489  |a Möller, Maximilian  |m 1346320489:Möller, Maximilian  |d 60000  |e 60000PM1346320489  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1906964521  |e 4602962068 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["1906964521"],"doi":["10.3389/fimmu.2024.1403771"]},"recId":"1906964521","type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Maximilian Möller, Vanessa Orth, Viktor Umansky, Svetlana Hetjens, Volker Braun, Christoph Reißfelder, Julia Hardt and Steffen Seyfried"]},"language":["eng"],"relHost":[{"disp":"Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy systematic review and meta-analysisFrontiers in immunology","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Frontiers in immunology","title":"Frontiers in immunology"}],"part":{"pages":"1-14","text":"15(2024), Artikel-ID 1403771, Seite 1-14","year":"2024","volume":"15","extent":"14"},"recId":"657998354","id":{"issn":["1664-3224"],"eki":["657998354"],"zdb":["2606827-8"]},"pubHistory":["1.2010 -"],"note":["Gesehen am 07.11.13"],"origin":[{"dateIssuedDisp":"2010-","publisher":"Frontiers Media","dateIssuedKey":"2010","publisherPlace":"Lausanne"}],"physDesc":[{"extent":"Online-Ressource"}]}],"title":[{"subtitle":"systematic review and meta-analysis","title":"Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy","title_sort":"Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy"}],"person":[{"role":"aut","display":"Möller, Maximilian","family":"Möller","given":"Maximilian"},{"family":"Orth","given":"Vanessa","role":"aut","display":"Orth, Vanessa"},{"display":"Umansky, Viktor","role":"aut","given":"Viktor","family":"Umansky"},{"display":"Hetjens, Svetlana","role":"aut","given":"Svetlana","family":"Hetjens"},{"role":"aut","display":"Braun, Volker","family":"Braun","given":"Volker"},{"given":"Christoph","family":"Reißfelder","role":"aut","display":"Reißfelder, Christoph"},{"role":"aut","display":"Hardt, Julia","family":"Hardt","given":"Julia"},{"display":"Seyfried, Steffen","role":"aut","family":"Seyfried","given":"Steffen"}],"physDesc":[{"extent":"14 S.","noteIll":"Illustrationen"}],"note":["Gesehen am 28.10.2024"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"24 May 2024"}]} 
SRT |a MOELLERMAXMYELOIDDER2420